Diabetic Retinopathy Market was valued at $966 million in 2015, and is expected to reach $2,490 million by 2022, supported by a CAGR of 14.4% during the forecast period 2014 to 2022. Diabetic retinopathy (DR) is an eye disease associated with diabetic patients. The disease occurs when there is damage to the retina due to diabetes. Without timely treatment, the disease may lead to bleeding in the eyes, cloudy vision, and may even destroy the retina. DR is amongst the common cause of loss of vision in the diabetic population; eventually leading to blindness.
Increase in prevalence of diabetes, rise in geriatric population, growth in incidence of blindness due to diabetes, and augment of focus on awareness that facilitates early diagnosis to control the diseases drive the market. However, this growth is limited by dearth of skilled ophthalmologists, and extended approval time for drugs. Conversely, emergence of combined therapies for treatment of diabetic macular edema and the emerging markets of the Asia-Pacific and LAMEA regions are expected to provide several opportunities for market growth during the forecast period.
Send Enquiry on this report @ https://www.alliedmarketresearch.com/purchase-enquiry/2010
Proliferative diabetic retinopathy segment accounted for a major market share in 2015 as the disease is one of the leading causes of blindness in diabetic patients. According to a 2014 NCBI article, nearly 1.5% of adults suffering from diabetes also have proliferative diabetic retinopathy (PDR), which is characterized by neovascularization of retina, leakage of serum, hemorrhage, and fibrovascular proliferation in the vitreous retinal interface. This further leads to vitreous hemorrhage and retinal detachment. Thus, if left untreated PDR may result into severe vision loss. Laser photocoagulation was one of the major methods to treat PDR during the past few years. Although photocoagulation showed excellent outcome in improving vision, it had its own drawbacks including paint during treatment and vitreous hemorrhage, which may even lead to loss of peripheral vision. Therefore, there was a need for newer modalities such as anti-VEGF for treating PDR. Anti-VEGF drugs are a group of medicines, which reduce new blood vessel growth or edema (swelling) in the eye. Anti-VEGF drugs overcome the drawbacks of laser treatment and thus the anti-VEGF market is expected to grow with a high CAGR during the forecast period.
Snapshot of Brazilian Diabetic Retinopathy Devices Market
Rise in focus of market vendors on emerging markets, namely, Asia-Pacific and LAMEA regions, is expected to boost the market growth. According to the estimates of The World Bank, the prevalence rate of diabetes was observed to be 10.4% in Brazilian population (age 20 to 79) in 2015. This accounts for nearly 14 million people suffering from diabetes in Brazil alone. As diabetes is one of the major risk factors for diabetic retinopathy, therefore increase in prevalence of diabetes is expected to lead to market growth. In addition, a 2014 article of NCBI reports that diabetic retinopathy was present in 7.62% of the Brazilian population that suffered from self-reported type 2 diabetes. Moreover, nearly 35.4% of patients diagnosed with diabetic retinopathy were unaware of the fact that they suffered from diabetes. In addition, prevalence of low vision and blindness is observed to be higher in individuals suffering from diabetes and DR. Therefore, there is a need for early diagnosis and treatment of diabetic retinopathy in the region. Thus, Brazil offers a huge customer base to the key players of diabetic retinopathy industry.
The diabetic retinopathy market witnessed several clinical trials in the recent years. North America accounted for the maximum number of trials (397) followed by Europe (237). Asia-Pacific and LAMEA accounted for a share of 20.2% (190) and 12.2% (115) respectively for the clinical trials in diabetic retinopathy market.
The list of key players profiled in this report include Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals., Bayer AG, F. Hoffmann-La Roche, Novartis International AG, Pfizer, Regeneron Pharmaceuticals Inc., and Valeant Pharmaceutical.
Download Sample Report @ https://www.alliedmarketresearch.com/request-sample/2010
Key players in the value chain include Boehringer Ingelheim GmbH, KOWA Company, Ltd., BCN Peptides S.A., and ThromboGenics NV.
- This report provides an extensive analysis of the current and emerging market trends and dynamics in the global diabetic retinopathy market.
- Comprehensive analysis of geographical regions is provided to determine the prevailing opportunities in the market.
- This study provides the competitive landscape of the market to predict the competitive environment across geographies.
- This report entails the detailed quantitative analysis of the current market and estimations from 2014 to 2022 to identify the prevailing opportunities.
- Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
- Region- and country-wise diabetic retinopathy market conditions are comprehensively analyzed in the report to understand the regional trends and dynamics.
Diabetic Retinopathy Market Key Segments
- Proliferative Diabetic Retinopathy
- Diabetic Macular Edema (DME)
By Treatment Type
- Anti VEGF Drug
- Steroid Implants
- Laser Surgeries
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- South Africa
- Saudi Arabia
- Rest of LAMEA
For More Info on this Report, Visit @ https://www.medgadget.com/2019/01/diabetic-retinopathy-market-growth-opportunity-and-industry-revenue-analysis-by-major-players-2014-2022.html